- Raw materials
- Hormonal Agents
- Bombesin
Bombesin API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Bombesin | CAS No: 31362-50-2 | GMP-certified suppliers
A medication that serves as an investigational peptide for diagnostic imaging and pharmacokinetic studies in prostate cancer and related neuropeptide research.
Therapeutic categories
Product Snapshot
- Bombesin is an investigational peptide formulation primarily designed for injectable administration
- Its main therapeutic use involves diagnostic imaging and potential targeted cancer therapies
- It is currently under clinical evaluation and does not have FDA or EMA approval
Clinical Overview
As an endogenous peptide, bombesin interacts with specific G-protein coupled receptors, such as Bombesin Receptor Subtype 2 (BB2), modulating diverse physiological processes. However, precise clinical pharmacodynamics and mechanism of action details relevant to human therapy remain to be fully elucidated. The molecule belongs to a broader category that encompasses amino acids, peptides, proteins, and some components derived from biological venoms.
Data on absorption, distribution, metabolism, and excretion (ADME) parameters for bombesin in human subjects are limited outside investigational settings. The ongoing clinical trial assesses plasma pharmacokinetics and biodistribution, which will inform formulation and clinical use considerations once data mature.
Safety and toxicity profiles are currently under review in clinical studies; no definitive adverse effect spectrum has been established. Given bombesin’s classification and investigational status, risk assessment focuses on tolerability during diagnostic applications.
From a sourcing perspective, procurement of bombesin as an active pharmaceutical ingredient requires stringent quality control to ensure peptide purity, stability, and activity, typically verified through analytical methods such as high-performance liquid chromatography (HPLC) and mass spectrometry. Suppliers should provide well-characterized material compliant with regulatory expectations for clinical research-grade peptides.
Identification & chemistry
| Generic name | Bombesin |
|---|---|
| Molecule type | Small molecule |
| CAS | 31362-50-2 |
| UNII | PX9AZU7QPK |
| DrugBank ID | DB11724 |
Formulation & handling
- Bombesin is a small molecule with high hydrophilicity indicated by a very low LogP value, suggesting limited membrane permeability and potential challenges in oral bioavailability. Its low aqueous solubility requires formulation strategies to enhance dissolution or alternative delivery routes, possibly injectable. Stability data is not provided, so handling under controlled conditions to prevent degradation is advised.
Regulatory status
Bombesin is a type of Hormonal Agents
Hormonal agents are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the medical field. These substances play a crucial role in regulating and modulating hormonal functions within the body. Hormonal agents are designed to mimic or manipulate the effects of naturally occurring hormones, allowing healthcare professionals to treat various endocrine disorders and hormonal imbalances.
Hormonal agents are commonly employed in the treatment of conditions such as hypothyroidism, hyperthyroidism, diabetes, and hormonal cancers. These APIs work by interacting with specific hormone receptors, either by stimulating or inhibiting their activity, to restore the balance of hormones in the body. They can be administered orally, intravenously, or through other routes depending on the specific medication and patient needs.
Pharmaceutical companies employ rigorous manufacturing processes and quality control measures to ensure the purity, potency, and safety of hormonal agent APIs. These APIs are synthesized using chemical or biotechnological methods, often starting from natural hormone sources or through recombinant DNA technology. Stringent regulatory guidelines are in place to guarantee the efficacy and safety of hormonal agent APIs, ensuring that patients receive high-quality medications.
As the demand for hormone-related therapies continues to grow, ongoing research and development efforts focus on enhancing the effectiveness and reducing the side effects of hormonal agent APIs. This includes the exploration of novel delivery systems, advanced formulations, and targeted drug delivery methods. By continuously advancing our understanding and capabilities in hormonal agents, the medical community can improve patient outcomes and quality of life for individuals with hormonal disorders.
